Global Sexually Transmitted Diseases (STD) Testing
Global Sexually Transmitted Diseases (STD) Testing

Sexually Transmitted Diseases (STD) Testing Comprehensive Study by Application (Clinical, Hospital, Camps), Disease Type (Chlamydia, Gonorrhea, Herpes simplex virus, Syphilis, Human papillomavirus (HPV), Others) Players and Region - Global Market Outlook to 2026

Sexually Transmitted Diseases (STD) Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 226 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Sexually Transmitted Diseases (STD) Testing Market Scope
Sexually Transmitted Diseases (STD) are infections that are transmitted from one person to another during vaginal, anal, and oral sex. Sexually Transmitted Diseases (STD) Testing are used for Diagnostics for STD Disease such as HIV. The demand for the STD test Market is huge due to rapid urbanization and increasing disease.

The Sexually Transmitted Diseases (STD) Testing market study is segmented, by Application (Clinical, Hospital and Camps) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. The market is expected to grow in the healthcare industry. It has wide application for the prevention of various STD such as HIV. Several companies are operating in the market to provide customers better with various features products & unique offering prices. The market is a partially fragmented market with the presence of several market players and local players. The demand in the market is huge which is triggering the market growth over the forecast period

STD Check (United States), myLAB Box (United States), HealthLabs (United States), Nurx (United States), Priority STD (United States), QuestDirect (United States), LetsGetChecked (Ireland), EverlyWell (United States) and Others are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Sexually Transmitted Diseases (STD) Testing market by Type, Application and Region.

On the basis of geography, the market of Sexually Transmitted Diseases (STD) Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On September 2021 Mylab has to acquire a majority stake in Sanskritech
On March 2021 Linear Diagnostics Eyeing has Launched for the Point-of-Care STD Testing Platform


Market Trend
  • Painless vaccination for end-user

Market Drivers
  • Rising demand for multipurpose technologies

Opportunities
  • Development of new STI vaccines that would boost sexually transmitted infection prevention

Restraints
  • cost of vaccination is huge

Challenges
  • Lack of provider and public awareness about screening recommendations


Key Target Audience
Laboratory, Regulatory Authorities, New Entrants/Investors, Strategic Business Planners, Governments and End-use Industry

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Sexually Transmitted Diseases (STD) Testing Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Application
  • Clinical
  • Hospital
  • Camps
By Disease Type
  • Chlamydia
  • Gonorrhea
  • Herpes simplex virus
  • Syphilis
  • Human papillomavirus (HPV)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising demand for multipurpose technologies
    • 3.3. Market Challenges
      • 3.3.1. Lack of provider and public awareness about screening recommendations
    • 3.4. Market Trends
      • 3.4.1. Painless vaccination for end-user
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sexually Transmitted Diseases (STD) Testing, by Application, Disease Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Sexually Transmitted Diseases (STD) Testing (Value)
      • 5.2.1. Global Sexually Transmitted Diseases (STD) Testing by: Application (Value)
        • 5.2.1.1. Clinical
        • 5.2.1.2. Hospital
        • 5.2.1.3. Camps
      • 5.2.2. Global Sexually Transmitted Diseases (STD) Testing by: Disease Type (Value)
        • 5.2.2.1. Chlamydia
        • 5.2.2.2. Gonorrhea
        • 5.2.2.3. Herpes simplex virus
        • 5.2.2.4. Syphilis
        • 5.2.2.5. Human papillomavirus (HPV)
        • 5.2.2.6. Others
      • 5.2.3. Global Sexually Transmitted Diseases (STD) Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Sexually Transmitted Diseases (STD) Testing (Price)
  • 6. Sexually Transmitted Diseases (STD) Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. STD Check (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. MyLAB Box (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. HealthLabs (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nurx (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Priority STD (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QuestDirect (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LetsGetChecked (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. EverlyWell (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Others
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Sexually Transmitted Diseases (STD) Testing Sale, by Application, Disease Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Sexually Transmitted Diseases (STD) Testing (Value)
      • 7.2.1. Global Sexually Transmitted Diseases (STD) Testing by: Application (Value)
        • 7.2.1.1. Clinical
        • 7.2.1.2. Hospital
        • 7.2.1.3. Camps
      • 7.2.2. Global Sexually Transmitted Diseases (STD) Testing by: Disease Type (Value)
        • 7.2.2.1. Chlamydia
        • 7.2.2.2. Gonorrhea
        • 7.2.2.3. Herpes simplex virus
        • 7.2.2.4. Syphilis
        • 7.2.2.5. Human papillomavirus (HPV)
        • 7.2.2.6. Others
      • 7.2.3. Global Sexually Transmitted Diseases (STD) Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Sexually Transmitted Diseases (STD) Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sexually Transmitted Diseases (STD) Testing: by Application(USD Million)
  • Table 2. Sexually Transmitted Diseases (STD) Testing Clinical , by Region USD Million (2015-2020)
  • Table 3. Sexually Transmitted Diseases (STD) Testing Hospital , by Region USD Million (2015-2020)
  • Table 4. Sexually Transmitted Diseases (STD) Testing Camps , by Region USD Million (2015-2020)
  • Table 5. Sexually Transmitted Diseases (STD) Testing: by Disease Type(USD Million)
  • Table 6. Sexually Transmitted Diseases (STD) Testing Chlamydia , by Region USD Million (2015-2020)
  • Table 7. Sexually Transmitted Diseases (STD) Testing Gonorrhea , by Region USD Million (2015-2020)
  • Table 8. Sexually Transmitted Diseases (STD) Testing Herpes simplex virus , by Region USD Million (2015-2020)
  • Table 9. Sexually Transmitted Diseases (STD) Testing Syphilis , by Region USD Million (2015-2020)
  • Table 10. Sexually Transmitted Diseases (STD) Testing Human papillomavirus (HPV) , by Region USD Million (2015-2020)
  • Table 11. Sexually Transmitted Diseases (STD) Testing Others , by Region USD Million (2015-2020)
  • Table 12. South America Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2015-2020)
  • Table 13. South America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 14. South America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 15. Brazil Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 16. Brazil Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 17. Argentina Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 18. Argentina Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 19. Rest of South America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 20. Rest of South America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 21. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 23. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 24. China Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 25. China Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 26. Japan Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 27. Japan Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 28. India Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 29. India Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 30. South Korea Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 31. South Korea Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 32. Taiwan Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 33. Taiwan Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 34. Australia Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 35. Australia Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 38. Europe Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2015-2020)
  • Table 39. Europe Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 40. Europe Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 41. Germany Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 42. Germany Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 43. France Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 44. France Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 45. Italy Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 46. Italy Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 47. United Kingdom Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 48. United Kingdom Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 49. Netherlands Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 50. Netherlands Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 51. Rest of Europe Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 52. Rest of Europe Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 53. MEA Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2015-2020)
  • Table 54. MEA Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 55. MEA Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 56. Middle East Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 57. Middle East Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 58. Africa Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 59. Africa Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 60. North America Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2015-2020)
  • Table 61. North America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 62. North America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 63. United States Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 64. United States Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 65. Canada Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 66. Canada Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 67. Mexico Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2015-2020)
  • Table 68. Mexico Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2015-2020)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Sexually Transmitted Diseases (STD) Testing: by Application(USD Million)
  • Table 79. Sexually Transmitted Diseases (STD) Testing Clinical , by Region USD Million (2021-2026)
  • Table 80. Sexually Transmitted Diseases (STD) Testing Hospital , by Region USD Million (2021-2026)
  • Table 81. Sexually Transmitted Diseases (STD) Testing Camps , by Region USD Million (2021-2026)
  • Table 82. Sexually Transmitted Diseases (STD) Testing: by Disease Type(USD Million)
  • Table 83. Sexually Transmitted Diseases (STD) Testing Chlamydia , by Region USD Million (2021-2026)
  • Table 84. Sexually Transmitted Diseases (STD) Testing Gonorrhea , by Region USD Million (2021-2026)
  • Table 85. Sexually Transmitted Diseases (STD) Testing Herpes simplex virus , by Region USD Million (2021-2026)
  • Table 86. Sexually Transmitted Diseases (STD) Testing Syphilis , by Region USD Million (2021-2026)
  • Table 87. Sexually Transmitted Diseases (STD) Testing Human papillomavirus (HPV) , by Region USD Million (2021-2026)
  • Table 88. Sexually Transmitted Diseases (STD) Testing Others , by Region USD Million (2021-2026)
  • Table 89. South America Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2021-2026)
  • Table 90. South America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 91. South America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 92. Brazil Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 93. Brazil Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 94. Argentina Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 95. Argentina Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 96. Rest of South America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 97. Rest of South America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 98. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2021-2026)
  • Table 99. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 100. Asia Pacific Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 101. China Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 102. China Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 103. Japan Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 104. Japan Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 105. India Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 106. India Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 107. South Korea Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 108. South Korea Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 109. Taiwan Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 110. Taiwan Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 111. Australia Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 112. Australia Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 113. Rest of Asia-Pacific Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 114. Rest of Asia-Pacific Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 115. Europe Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2021-2026)
  • Table 116. Europe Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 117. Europe Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 118. Germany Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 119. Germany Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 120. France Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 121. France Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 122. Italy Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 123. Italy Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 124. United Kingdom Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 125. United Kingdom Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 126. Netherlands Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 127. Netherlands Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 128. Rest of Europe Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 129. Rest of Europe Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 130. MEA Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2021-2026)
  • Table 131. MEA Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 132. MEA Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 133. Middle East Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 134. Middle East Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 135. Africa Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 136. Africa Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 137. North America Sexually Transmitted Diseases (STD) Testing, by Country USD Million (2021-2026)
  • Table 138. North America Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 139. North America Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 140. United States Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 141. United States Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 142. Canada Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 143. Canada Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 144. Mexico Sexually Transmitted Diseases (STD) Testing, by Application USD Million (2021-2026)
  • Table 145. Mexico Sexually Transmitted Diseases (STD) Testing, by Disease Type USD Million (2021-2026)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sexually Transmitted Diseases (STD) Testing: by Application USD Million (2015-2020)
  • Figure 5. Global Sexually Transmitted Diseases (STD) Testing: by Disease Type USD Million (2015-2020)
  • Figure 6. South America Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 7. Asia Pacific Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 8. Europe Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 9. MEA Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 10. North America Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 11. Global Sexually Transmitted Diseases (STD) Testing share by Players 2020 (%)
  • Figure 12. Global Sexually Transmitted Diseases (STD) Testing share by Players (Top 3) 2020(%)
  • Figure 13. Global Sexually Transmitted Diseases (STD) Testing share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. STD Check (United States) Revenue, Net Income and Gross profit
  • Figure 16. STD Check (United States) Revenue: by Geography 2020
  • Figure 17. MyLAB Box (United States) Revenue, Net Income and Gross profit
  • Figure 18. MyLAB Box (United States) Revenue: by Geography 2020
  • Figure 19. HealthLabs (United States) Revenue, Net Income and Gross profit
  • Figure 20. HealthLabs (United States) Revenue: by Geography 2020
  • Figure 21. Nurx (United States) Revenue, Net Income and Gross profit
  • Figure 22. Nurx (United States) Revenue: by Geography 2020
  • Figure 23. Priority STD (United States) Revenue, Net Income and Gross profit
  • Figure 24. Priority STD (United States) Revenue: by Geography 2020
  • Figure 25. QuestDirect (United States) Revenue, Net Income and Gross profit
  • Figure 26. QuestDirect (United States) Revenue: by Geography 2020
  • Figure 27. LetsGetChecked (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. LetsGetChecked (Ireland) Revenue: by Geography 2020
  • Figure 29. EverlyWell (United States) Revenue, Net Income and Gross profit
  • Figure 30. EverlyWell (United States) Revenue: by Geography 2020
  • Figure 31. Others Revenue, Net Income and Gross profit
  • Figure 32. Others Revenue: by Geography 2020
  • Figure 33. Global Sexually Transmitted Diseases (STD) Testing: by Application USD Million (2021-2026)
  • Figure 34. Global Sexually Transmitted Diseases (STD) Testing: by Disease Type USD Million (2021-2026)
  • Figure 35. South America Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 36. Asia Pacific Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 37. Europe Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 38. MEA Sexually Transmitted Diseases (STD) Testing Share (%), by Country
  • Figure 39. North America Sexually Transmitted Diseases (STD) Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • STD Check (United States)
  • myLAB Box (United States)
  • HealthLabs (United States)
  • Nurx (United States)
  • Priority STD (United States)
  • QuestDirect (United States)
  • LetsGetChecked (Ireland)
  • EverlyWell (United States)
  • Others
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation